Men treated with ADT more likely to experience impaired cognitive performance
the ONA take:
Men treated with androgen deprivation therapy (ADT) for prostate cancer were more likely to demonstrate impaired cognitive performance within 6 months and for up to 12 months after initiation of ADT, a new study published online early in the Journal of Clinical Oncology has shown.
For the study, researchers at Moffitt Cancer Center in Tampa, Florida, sought to determine the effect of ADT on cognitive performance identify predictors of impaired performance. Researchers enrolled 58 patients with prostate cancer whom they assessed before or within 21 days of starting ADT and 6 and 12 months afterwards.
Participants were compared with matched controls with prostate cancer treated with prostatectomy as well as men with without prostate cancer.
Results showed that participants that received ADT had higher rates of impaired cognitive performance over time compared with all controls.
Researchers found that those who received ADT were more likely to exhibit impaired performance within 6 and 12 months versus the other two groups despite no differences in baseline characteristics.
Exploratory genetic analyses showed that GNB3 single-nucleotide polymorphism rs1047776 was associated with higher rates of impaired cognitive performance over time in patients treated with ADT.
The findings may result in changes to patient education regarding the benefits and risks of ADT.
Men treated with ADT for prostate cancer more likely to demonstrate impaired cognitive performance.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|